STM publisher Elsevier has announced that it has acquired Neoplasia Press Inc. and assumes publication of its flagship journals, Neoplasia and Translational Oncology. These peer-reviewed, open access journals will now be published by Elsevier under the Neoplasia Press imprint.
With a significant Impact Factor of 5.398, Neoplasia is a well-established cancer research journal that publishes the results of novel investigations in all areas of oncology research. Under the editorial leadership of Dr. Alnawaz Rehemtulla, Ruth Tuttle Freeman Research Professor and Director of the Molecular Imaging Division, Department of Radiation Oncology, University of Michigan, the journal's breadth encompasses not only the traditional disciplines of cancer research, but also emerging fields and interdisciplinary investigations. Published monthly, Neoplasia features studies describing new molecular and genetic findings relating to the neoplastic phenotype and laboratory and clinical studies demonstrating creative applications of advances in the basic sciences to risk assessment, prognostic indications, detection, diagnosis, and treatment.
Sister publication Translational Oncology was successfully launched in 2008 and publishes the results of novel research investigations that bridge the laboratory and clinical settings, including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis, and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Guided by Editor-in-Chief Dr. Theodore S. Lawrence, Isadore Lampe Professor and Department Chair, Department of Radiation Oncology, University of Michigan, this bimonthly journal publishes laboratory studies of novel therapeutic interventions as well as clinical trials that evaluate new treatment paradigms for cancer.
Neoplasia and Translational Oncology are available on their own dedicated Elsevier sites as well as via ScienceDirect, Elsevier's full-text platform for the library community. Both journals are included in PubMed and PubMed Central, increasing the discoverability of their content by researchers, clinicians and other healthcare professionals worldwide.
